This downregulation of KIT expression is even more pronounced in poor prognosis systemic mastocytosis (i.e. systemic mastocytosis associated with a clonal hematopoietic disease, aggressive systemic mastocytosis and mast cell leukemia) [39], suggesting that multiple layers of regulation of this receptor may be acting in diseased cells. The gene discussed is KIT; the disease is hematologic disorder.